Aurora, Colorado.
Trans Am Clin Climatol Assoc. 2024;134:113-122.
Adrenocortical carcinoma (ACC) is an orphan cancer with 35% five-year survival that has been unchanged for last five decades. Patients often present with severe hypercortisolism or with mass effects. The only Food and Drug Administration (FDA)-approved drug for ACC is mitotane, an insecticide derivative, which provides only limited additional months of survival, but with toxicities. Little progress in the field has occurred due to a lack of preclinical models. We recently developed new human ACC and research models. We produced the first two new ACC cell lines for the field, CU-ACC1 and CU-ACC2, which we have distributed for global collaborations. In addition, we developed 10 ACC patient-derived xenograft (PDX) and two humanized ACC-PDX models to test new therapeutics and examine the mechanism of mitotane action in combination with immunotherapy. These new preclinical models allow us to identify novel targets and test new therapeutics for our patients with adrenal cancer.
肾上腺皮质癌（ACC）是一种罕见的癌症，其五年生存率为 35%，在过去五十年中没有改变。患者常表现为严重的皮质醇增多症或肿块效应。唯一获得美国食品和药物管理局（FDA）批准用于 ACC 的药物是米托坦，一种杀虫剂衍生物，只能提供有限的额外生存时间，但具有毒性。由于缺乏临床前模型，该领域几乎没有取得进展。我们最近开发了新的人源 ACC 和研究模型。我们为该领域生产了前两条新的 ACC 细胞系，CU-ACC1 和 CU-ACC2，我们已将其分发给全球合作机构。此外，我们还开发了 10 种 ACC 患者来源的异种移植（PDX）和两种人源化 ACC-PDX 模型，以测试新的治疗方法，并研究米托坦与免疫疗法联合作用的机制。这些新的临床前模型使我们能够确定新的靶点，并为患有肾上腺癌的患者测试新的治疗方法。
